Michael S. B. Edwards M.D.

Publication Details

  • Long-term follow-up after high-activity I-125 brachytherapy for pediatric brain tumors PEDIATRIC NEUROSURGERY Sneed, P. K., Russo, C., SCHARFEN, C. O., Prados, M. D., Malec, M. K., Larson, D. A., Lamborn, K. R., Lamb, S. A., Voss, B., Weaver, K. A., Phillips, T. L., Gutin, P. H., Wara, W. M., Edwards, M. S. 1996; 24 (6): 314-322


    A retrospective review including long-term follow-up (4.6-12.0 years) was performed of all 28 pediatric patients who underwent high-activity 125I brachytherapy at the University of California, San Francisco, for primary or recurrent brain tumors from 1980 until 1991. There were 4 glioblastomas, 11 high-grade nonglioblastoma multiforme (NGM) malignant gliomas, 10 contrast-enhancing low-grade NGM, 2 choroid plexus carcinomas, and 1 rhabdomyosarcoma. The 13 survivors included 7 of 8 patients with primary high-grade NGM, 2 of 3 patients with primary low-grade NGM, and 3 of 7 patients with recurrent low-grade NGM. Necrosis (with or without tumor) was identified in 17 of 22 reoperated patients. The mean Karnofsky performance status was 88 +/- 9 at the time of brachytherapy, 87 +/- 7 at 3 years, and 87 +/- 9 in 11 patients alive at 6-12 years. Brachytherapy is a useful modality for treating selected pediatric brain tumors, and although focal necrosis is a common sequela, it does not tend to have a major impact on the Karnofsky performance status, if the implant site is amenable to reoperation.

    View details for Web of Science ID A1996VX56800006

    View details for PubMedID 8988497

Stanford Medicine Resources:

Footer Links: